Chemistry:Bleselumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Clinical data | |
| Other names | ASKP1240 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6412H9906N1690O2018S38 |
| Molar mass | 144175.87 g·mol−1 |
Bleselumab (INN;[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.[2][3]
This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.[4]
References
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113". WHO Drug Information 29 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf.
- ↑ "Current status of costimulatory blockade in renal transplantation". Current Opinion in Nephrology and Hypertension 25 (6): 583–590. November 2016. doi:10.1097/MNH.0000000000000268. PMID 27517137.
- ↑ "Costimulation Blockade in Kidney Transplantation: An Update". Transplantation 100 (11): 2315–2323. November 2016. doi:10.1097/TP.0000000000001344. PMID 27472094.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.
 |  |
